Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2014
  • Online publication date: March 2014

Chapter 18 - Hepatitis B virus infection

from Section III - Hepatitis and immune disorders

Related content

Powered by UNSILO
References
Ganem, D, Prince, AM. Hepatitis B virus infection natural history and clinical consequences. N Engl J Med 2004;350:1118–1129.
Hsu, HY, Chang, MH, Chen, DS, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301–307.
Nassal, M. Hepatitis B viruses: Reverse transcription a different way. Virus Research 2008;134:235–249.
Murray, JM, Purcell, R, Wieland, SF. The half life of hepatitis B virions. Hepatology 2006;44:1117–1121.
Balistreri, WF. Viral hepatitis. Emerg Clin North Am 1991;9:365–399.
Hoofnagle, JH, DiBisceglie, AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991;11:73–83.
Andersson, KL, Raymond, T, Chung, RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009;49:S166–S173.
McQuillan, GM, Coleman, PJ, Kruszon-Moran, D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14–18.
Custer, B, Sullivan, SD, Hazlet, TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158–S168.
Feret, E, Larouze, B, Diop, B, et al. Epidemiology of hepatitis B virus infection in the rural community of Tip, Senegal. Am J Epidemiol 1987;125:140–149.
Beasley, RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009;19:231–234.
Hsu, HY, Chang, MH, Hsieh, KH, et al. Cellular immune response to hepatitis B core antigen in maternal infant transmission of hepatitis B virus. Hepatology 1992;15:770–776.
Lee, SD, Lo, KJ, Tsai, YT, et al. Role of caesarian section in the prevention of mother-to-infant transmission of the hepatitis B virus. Lancet 1988;ii:833–834.
Tang, JR, Hsu, HY, Lin, HH, et al. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998;133:374–377.
Li, XM, Shi, MF, Yang, YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004;10:3215–3217.
Beasley, RP, Stevens, CE, Shiao, IS, Meng, HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2:740–741.
Gartner, LM, Morton, J, Lawrence, RA, et al. Breastfeeding and the use of human milk. Pediatrics 2005;115:496–506.
Bhaduri, BR, Mieli-Vergani, G. Fulminant hepatic failure: pediatric aspects. Semin Liver Dis 1996;16:349–355.
Chang, MH, Lee, CY, Chen, DS, Hsu, HC, Lai, MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr 1987;111:34–39.
Hsu, HY, Chang, MH, Lee, CY, et al. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis 1995;171:776–781.
Chang, MH, Hsu, HY, Hsu, HC, et al. The significance of spontaneous HBeAg seroconversion in childhood: with special emphasis on the clearance of HBeAg before three years of age. Hepatology 1995;22:1387–1392.
Chu, CM, Karayiannis, P, Fowler, MJ, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431–434.
Bortolotti, F, Cadrobbi, M, Crivellaro, C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus in infection in childhood. Gastroenterology 1990;99:805–810.
Chang, MH, Sung, JL, Lee, CY, et al. Factors affecting the clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr 1989;115:385–390.
Wu, JF, Su, YR, Chen, CH, et al. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children. J Pediatr Gastroenterol Nutr 2012;54:97–100.
Bortolotti, F, Guido, M, Bartolacci, S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556–562.
Bortolotti, F, Wirth, S, Crivellaro, C, et al. Long-term persistence of hepatitis B virus DNA in the serum of children with chronic hepatitis B after hepatitis B e antigen to antibody seroconversion. J Pediatr Gastroenterol Nutr 1996;22:270–274.
Chu, CM, Liaw, YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hep Intl 2007;1:311–315.
Liaw, YF. Natural historyof chronic hepatitis B virus infection and long-term outcome under treatment. Liver International 2009;29(s1):100–107.
Ni, YH, Chang, MH, Chen, PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007;132:2340–2345.
Hsu, HY, Chang, MH, Lee, CY, et al. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology 1992;15;382–386.
Chu, CM, Liaw, YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187–1192.
Chang, MH, Hwang, LY, Hsu, HC, Lee, CY, Beasley, RP. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology 1988;8:374–377.
Hsu, HC, Lin, YH, Chang, MH, et al. Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens. Hepatology 1988;8:378–382.
Tseng, YR, Wu, JF, Ni, YH, et al. Long-term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection. Liver Int 2011;31:1373–1380.
Wu, JF, Wu, TC, Chen, CH, et al. Serum levels of interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversiston. Gastroenterology 2010;138:165–172.
Lin, CL, Kao, JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011;26(Suppl 1):123–130.
Ni, YH, Chang, MH, Wang, KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic hepatitis B and hepatocellular carcinoma. Gastroenterology 2004;127:1733–1738.
Chen, CJ, Yang, HI, Iloeje, UH, for the REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009;49(5 Suppl):S72–S84.
Chang, MH, Hsu, HY, Ni, YH, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: Its relation to hepatitis B e seroconversion and natural hepatitis B surface antigen. J Hepatol 1998;28:915–922.
Ni, YH, Chang, MH, Hsu, HY, Tsuei, DJ. Longitudinal study on mutation profiles of core promoter and precore regions of the hepatitis B virus genome in children. Pediatr Res 2004;56:396–399.
Ni, YH, Chang, MH, Hsu, HY, Tsuei, DJ. Different hepatitis B virus core gene mutations in children with chronic infection versus hepatocellular carcinoma. Gut 2003;52:122–125.
Jonas, MM, Block, JM, Haber, BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010;52:2192–2205.
Torre, D, Tambini, R. Interferon-α therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131–137.
Sokal, EM, Conjeevaram, HS, Roberts, EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988–995.
Bortolotti, F, Jara, P, Barbera, C, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715–718.
Hsu, HY, Tsai, HY, Wu, TC, et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008;28:1288–1297.
Schwarz, KB, Gonzalez-Peralta, RP, Murray, KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450–458.
Jonas, M, Kelly, DA, Mizerski, J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706–1713.
Sokal, EM, Kelly, DA, Badia, IB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225–232.
Jonas, MM, Kelly, D, Pollack, H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008;47:1863–1871.
Chang, TT, Gish, RG, de Man, R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001–1010.
Lai, CL, Shouval, D, Lok, AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–1020.
Tenney, DJ, Rose, RE, Baldick, CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside- naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503–14.
Lai, CL, Gane, E, Liaw, YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576–2588.
Seto, WK, Lai, CL, Fung, J, et al. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2011;55:522–528.
Marcellin, P, Heathcote, EJ, Buti, M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–2455.
Heathcote, EJ, Marcellin, P, Buti, M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132–143.
D’Antiga, L, Aw, M, Atkins, M, et al. Combined lamivudine/interferon-alpha treatment in “immunotolerant” children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006;148:228–233.
Chen, HL, Lin, LH, Hu, FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012;142:773–781.
Chen, DS, Hsu, NH, Sung, JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987;257:2597–2603.
Bonanni, P, Crovari, P. Success stories in the implementation of universal hepatitis B vaccination: an update on Italy. Vaccine 1998;16(Suppl):S38–S42.
Wasley, A, Grytdal, S, Gallagher, K; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis: United States, 2006. MMWR Surveill Summ 2008;57:1–24.
Ni, YH, Huang, LM, Chang, MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287–1293.
Viviani, S, Jack, A, Hall, AJ, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999;17:2946–2950.
Kao, JH, Hsu, HM, Shaw, WY, Chang, MH, Chen, DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349–352.
Chang, MH, Chen, CJ, Lai, MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855–1859.
Chang, MH, You, SL, Chen, CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348–1355.
Su, WJ, Ho, MC, Ni, YH, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203–208.
Hsu, HY, Chang, MH, Ni, YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010;201:1192–1200.
Centers for Disease Control and Prevention. Hepatitis B Slide Set. Atlanta, GA: Centers for Disease Control and Prevention, 2006 (, accessed January 26, 2006).
Rizzetto, M, Canese, MG, Arico, S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977;18:997–1003.
Fattowich, G, Giustina, G, Christensen, E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000;46:420–426.
Bortolotti, F, Di Marco, V, Vajro, P, et al. Long-term evolution of chronic delta hepatitis in children. J Pediatr 1993;122:736–738.
Mele, A, Mariano, A, Tosti, ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti–hepatitis B vaccination campaign. Clin Infect Dis 2007;44:e17–e24.
Di Marco, V, Giacchino, R, Timitilli, A, et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996;3:123–128.